TITLE

BRAND-NAME PRESCRIPTION DRUG PRICING: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases

PUB. DATE
January 2010
SOURCE
GAO Reports;1/11/2010, preceding p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The article highlights the study of Government Accountability Office (GAO) which examines the growing cost of brand-name prescription drugs with extraordinary price increase in the U.S. It notes that Food and Drug Administration-approved drug products that have patent protection concern the patients, payers and providers of health care when the prices increase suddenly in large amount. In this regard, GAO examines the extraordinary price increase for the brand-name price increase.
ACCESSION #
47731686

 

Share

Read the Article

Other Topics